Want to see SE:BOUL full AI Analyst Report?
BOUL Stock Chart & Stats
kr2.71
-kr0.09(-3.21%)
―
--
Day’s Range― - ―
52-Week Rangekr2.71 - kr6.64
Previous CloseN/A
VolumeN/A
Average Volume (3M)38.37K
Market Cap
kr108.73M
Enterprise Valuekr351.77
Total Cash (Recent Filing)kr19.60M
Total Debt (Recent Filing)kr227.30M
Price to Earnings (P/E)―
Beta0.71
Next Earnings
Oct 23, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend Yield1.06%
Share Statistics
EPS (TTM)-0.10
Shares Outstanding38,833,103
10 Day Avg. Volume41,087
30 Day Avg. Volume38,374
Financial Highlights & Ratios
PEG Ratio0.50
Price to Book (P/B)1.11
Price to Sales (P/S)0.38
P/FCF Ratio-45.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.25
Revenue Forecast (FY)kr453.10M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables RevenueThe installed-base model can create repeat consumables revenue after an analyzer is placed, improving customer retention and revenue visibility. Service and support activities add another recurring or usage-linked stream, helping diversify income beyond initial instrument sales over the next several quarters.
Operating Profitability RecoveryA return to positive operating profit indicates that the core business has recovered materially from the 2024 downturn. Maintaining a mid-single-digit operating margin would support internal funding, strengthen resilience, and provide a base for rebuilding bottom-line profitability.
Improved Cash GenerationPositive operating and free cash flow provide useful support while reported net income remains slightly negative. This improvement can help fund operations, service debt, and support product investment without relying entirely on external financing, although consistency remains important.
Bears Say
Declining RevenueDeclining revenue signals that demand or commercial execution has not yet returned to durable growth after the earlier downturn. Continued top-line contraction can limit operating leverage, reduce reinvestment capacity, and make the recent profitability recovery harder to sustain.
Ongoing Net LossesPersistent net losses show that improved operating performance has not yet translated into consistent shareholder-level profitability. Until earnings turn sustainably positive, retained capital remains constrained and the company has less protection against weaker revenue or higher financing costs.
Higher LeverageThe sharp increase in leverage and decline in equity reduce financial flexibility at a time when revenue remains under pressure. A heavier debt burden can restrict capital allocation, increase sensitivity to earnings volatility, and raise the consequences of a prolonged recovery.
Boule Diagnostics AB News
BOUL FAQ
What was Boule Diagnostics AB’s price range in the past 12 months?
Boule Diagnostics AB lowest stock price was kr2.71 and its highest was kr6.64 in the past 12 months.
What is Boule Diagnostics AB’s market cap?
Boule Diagnostics AB’s market cap is kr108.73M.
When is Boule Diagnostics AB’s upcoming earnings report date?
Boule Diagnostics AB’s upcoming earnings report date is Oct 23, 2026 which is in 41 days.
How were Boule Diagnostics AB’s earnings last quarter?
Boule Diagnostics AB released its earnings results on Jul 17, 2026. The company reported -kr0.044 earnings per share for the quarter, missing the consensus estimate of kr0.01 by -kr0.054.
Is Boule Diagnostics AB overvalued?
According to Wall Street analysts Boule Diagnostics AB’s price is currently Undervalued.
Does Boule Diagnostics AB pay dividends?
Boule Diagnostics AB pays a Annually dividend of kr0.389 which represents an annual dividend yield of 1.06%. See more information on Boule Diagnostics AB dividends here
What is Boule Diagnostics AB’s EPS estimate?
Boule Diagnostics AB’s EPS estimate is -0.02.
How many shares outstanding does Boule Diagnostics AB have?
Boule Diagnostics AB has 38,833,103 shares outstanding.
What happened to Boule Diagnostics AB’s price movement after its last earnings report?
Boule Diagnostics AB reported an EPS of -kr0.044 in its last earnings report, missing expectations of kr0.01. Following the earnings report the stock price went down -8%.
Which hedge fund is a major shareholder of Boule Diagnostics AB?
Currently, no hedge funds are holding shares in SE:BOUL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Boule Diagnostics AB
Boule Diagnostics AB (publ) develops, manufactures, and markets instruments and consumable products for blood diagnostics in the United States of America, Asia, Eastern Europe, Latin America, Western Europe, Africa, and the Middle East. The company provides hematology analyzers, reagents, controls, and calibrators, under the Swelab, and Medonic brands; and veterinary hematology and clinical chemistry analyzer systems, as well as reagents and panels under the Exigo brand. It serves small and medium-sized hospitals, clinics, laboratories, and veterinary clinics, and other diagnostics firms. The company was founded in 1956 and is headquartered in Spånga, Sweden.